LOBE.F Stock Overview
A biopharmaceutical company, focuses on the research and development using sub-hallucinatory doses of proprietary psychedelic compounds to improve brain and mental health, and wellness.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lobe Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.028 |
| 52 Week Low | CA$0.01 |
| Beta | 2.41 |
| 11 Month Change | 8.57% |
| 3 Month Change | 25.62% |
| 1 Year Change | -30.91% |
| 33 Year Change | -96.77% |
| 5 Year Change | n/a |
| Change since IPO | -96.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| LOBE.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.0% | 3.4% | 1.0% |
| 1Y | -30.9% | 26.7% | 21.7% |
Return vs Industry: LOBE.F underperformed the US Pharmaceuticals industry which returned 26.7% over the past year.
Return vs Market: LOBE.F underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| LOBE.F volatility | |
|---|---|
| LOBE.F Average Weekly Movement | 24.4% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 14.7% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LOBE.F's share price has been volatile over the past 3 months.
Volatility Over Time: LOBE.F's weekly volatility has decreased from 31% to 24% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Phil Young | www.lobesciences.com |
Lobe Sciences Ltd., a biopharmaceutical company, focuses on the research and development using sub-hallucinatory doses of proprietary psychedelic compounds to improve brain and mental health, and wellness. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020.
Lobe Sciences Ltd. Fundamentals Summary
| LOBE.F fundamental statistics | |
|---|---|
| Market cap | US$1.89m |
| Earnings (TTM) | -US$2.09m |
| Revenue (TTM) | US$716.44k |
2.6x
P/S Ratio-0.9x
P/E RatioIs LOBE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOBE.F income statement (TTM) | |
|---|---|
| Revenue | CA$976.74k |
| Cost of Revenue | CA$25.77k |
| Gross Profit | CA$950.97k |
| Other Expenses | CA$3.80m |
| Earnings | -CA$2.85m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 97.36% |
| Net Profit Margin | -291.93% |
| Debt/Equity Ratio | -29.8% |
How did LOBE.F perform over the long term?
See historical performance and comparison